Columbia ranked fifth in Inc. Magazine and Fast Company's list of top 50 institutions revolutionizing entrepreneurship.
Columbia's Dr. Carol Troy was the winner of a 2024 XSeed Award. She received a $250K grant for her work to develop the first noninvasive treatment for retinal vascular occlusion.
Columbia's Dr. Gary W. Miller and Dr. David Sulzer were selected for the 2024 SPARK NS Parkinson’s Disease Translational Research Program, a two-year immersive program designed to advance academic discoveries in Parkinson’s disease from the lab to the clinic.
Columbia's Dr. Andrew Wang was featured in Chemical & Engineering News for applying his research to build a startup that could transform the future of energy storage. His company, Standard Potential, is commercializing a sodium-ion battery technology designed to reduce the cost of batteries.
Sable Therapeutics announced an exclusive license from Columbia for a portfolio of novel polycation nanomedicines to treat obesity, developed by Columbia's Dr. Kam Leong and former Columbia professor Dr. Li Qiang.
The Wall Street Journal featured a device invented by Columbia's Dr. Stavros Thomopoulos, Dr. Iden Kurtaliaj, and Dr. William Levine. The device is a a python-tooth-inspired implant to better mend rotator cuff tears.
The Columbia Lab-to-Market Accelerator Network worked alongside Empire State Development and Mount Sinai Innovation Partners to launch the 3rd round of the NYS Biodefense Commercialization Fund. Governor Hochul announced the 3rd round of awardees, including Rover Diagnostics and Dr. Ian Lipkin, who are developing technology from Columbia.
Columbia Engineering profiled Materialize New York, an accelerator led by Material Impact and Columbia Technology Ventures that gave students the opportunity to advance their lab research into a deeptech startup.
Allure Security, a Columbia startup developing cybersecurity software tools based on technology from the lab of Columbia's Dr. Salvatore Stolfo, closed a $10 million Series A funding round.
Gilgamesh Pharmaceuticals was awarded a multi-year $14M grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders. The startup is commercializing technology from the lab of Columbia's Dr. Dalibor Sames.
Gilgamesh Pharmaceuticals announced a new collaboration and option-to-license agreement with AbbVie aimed at developing novel transformative therapies for psychiatric disorders. The startup is commercializing technology from the lab of Columbia's Dr. Dalibor Sames.
olumbia startups Heirloom and 44.01 were named two of the finalist teams selected to compete in the last stage of XPRIZE Carbon Removal. Heirloom is based on a direct air capture system developed by Columbia's Dr. Peter Kelemen, and 44.01 uses technology developed by Dr. Peter Kelemen and Dr. Juerg Matter.